Cytostatic therapy for AA amyloidosis complicating psoriatic spondyloarthropathy

Psoriatic spondyloarthropathy (PSA) can occasionally be complicated by AA amyloid, and renal amyloidosis should be suspected in patients with PSA who have unexplained proteinuria. The diagnosis of amyloidosis can be made either histologically or by radiolabelled serum amyloid P component (SAP) scint...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of rheumatology 2003-02, Vol.42 (2), p.362-366
Hauptverfasser: Mpofu, S., Teh, L. S., Smith, P. J., Moots, R. J., Hawkins, P. N.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 366
container_issue 2
container_start_page 362
container_title British journal of rheumatology
container_volume 42
creator Mpofu, S.
Teh, L. S.
Smith, P. J.
Moots, R. J.
Hawkins, P. N.
description Psoriatic spondyloarthropathy (PSA) can occasionally be complicated by AA amyloid, and renal amyloidosis should be suspected in patients with PSA who have unexplained proteinuria. The diagnosis of amyloidosis can be made either histologically or by radiolabelled serum amyloid P component (SAP) scintigraphy. Prognosis is determined by the extent of organ involvement and associated impairment of function, and by the degree of response of the underlying disease to anti‐inflammatory therapy. A review of the literature identified less than a dozen cases of AA amyloidosis complicating PSA, and the outcome in most cases was poor. We report here the favourable clinical course of a middle‐aged Caucasian male patient with severe PSA who developed renal AA amyloidosis, in whom treatment with oral chlorambucil led to stabilization of the amyloid deposits and resolution of the associated nephrotic syndrome. We review the diagnosis and treatment of AA amyloidosis, including the management of patients with underlying inflammatory spondyloarthropathies, and propose the possible role of a therapeutic trial of anti‐tumour necrosis factor α in patients with amyloid complicating inflammatory rheumatic diseases.
doi_str_mv 10.1093/rheumatology/keg101
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73025194</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73025194</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-3d894a0f61e91c783a20dc08464551d999ecdcbdc66ac40912446075a1a1bc5d3</originalsourceid><addsrcrecordid>eNpd0F1rFDEUBuAgiv3QXyDIINi7scnka3K5LNoKC1ZREW_C2SSzm3ZmMk0y4Px7o7u04lUO5HkPhxehVwS_I1jRy7h38wA59GG3XN65HcHkCTolTDQ1prR5-jA37ASdpXSLMeaEts_RCWm44oLKU3SzXnJIGbI3Vd67CNNSdSFWq1UFw9IHb0PyqTJhmHpvCht31ZRC9H8TaQqjLQpi3scwQd4vL9CzDvrkXh7fc_Ttw_uv6-t68-nq43q1qQ1jJNfUtooB7gRxihjZUmiwNbhlgnFOrFLKGWu21ggBhmFFGsYElhwIkK3hlp6ji8PeKYb72aWsB5-M63sYXZiTlhQ3nChW4Jv_4G2Y41hu06SUwKVoaUH0gEwMKUXX6Sn6AeKiCdZ_2tb_tq0PbZfU6-PqeTs4-5g51lvA2yOAZKDvIozGp0fHOJVS8uLqg_Mpu18P_xDvtJBUcn3946f-rr7ctFebz3pNfwMLS50j</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>195657683</pqid></control><display><type>article</type><title>Cytostatic therapy for AA amyloidosis complicating psoriatic spondyloarthropathy</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Mpofu, S. ; Teh, L. S. ; Smith, P. J. ; Moots, R. J. ; Hawkins, P. N.</creator><creatorcontrib>Mpofu, S. ; Teh, L. S. ; Smith, P. J. ; Moots, R. J. ; Hawkins, P. N.</creatorcontrib><description>Psoriatic spondyloarthropathy (PSA) can occasionally be complicated by AA amyloid, and renal amyloidosis should be suspected in patients with PSA who have unexplained proteinuria. The diagnosis of amyloidosis can be made either histologically or by radiolabelled serum amyloid P component (SAP) scintigraphy. Prognosis is determined by the extent of organ involvement and associated impairment of function, and by the degree of response of the underlying disease to anti‐inflammatory therapy. A review of the literature identified less than a dozen cases of AA amyloidosis complicating PSA, and the outcome in most cases was poor. We report here the favourable clinical course of a middle‐aged Caucasian male patient with severe PSA who developed renal AA amyloidosis, in whom treatment with oral chlorambucil led to stabilization of the amyloid deposits and resolution of the associated nephrotic syndrome. We review the diagnosis and treatment of AA amyloidosis, including the management of patients with underlying inflammatory spondyloarthropathies, and propose the possible role of a therapeutic trial of anti‐tumour necrosis factor α in patients with amyloid complicating inflammatory rheumatic diseases.</description><identifier>ISSN: 1462-0324</identifier><identifier>ISSN: 1460-2172</identifier><identifier>EISSN: 1462-0332</identifier><identifier>EISSN: 1460-2172</identifier><identifier>DOI: 10.1093/rheumatology/keg101</identifier><identifier>PMID: 12595637</identifier><identifier>CODEN: BJRHDF</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>AA amyloidosis ; Amyloidosis - drug therapy ; Amyloidosis - etiology ; Anti‐TNF ; Arthritis, Psoriatic - complications ; Biological and medical sciences ; Chlorambucil ; Chlorambucil - therapeutic use ; Dermatology ; Follow-Up Studies ; Humans ; Kidney Diseases - drug therapy ; Kidney Diseases - etiology ; Male ; Medical sciences ; Middle Aged ; Psoriasis. Parapsoriasis. Lichen ; Psoriatic spondyloarthropathy ; Serum Amyloid A Protein - analysis ; Spondylarthropathies - complications</subject><ispartof>British journal of rheumatology, 2003-02, Vol.42 (2), p.362-366</ispartof><rights>2003 INIST-CNRS</rights><rights>Copyright Oxford University Press(England) Feb 2003</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-3d894a0f61e91c783a20dc08464551d999ecdcbdc66ac40912446075a1a1bc5d3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=14537775$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12595637$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mpofu, S.</creatorcontrib><creatorcontrib>Teh, L. S.</creatorcontrib><creatorcontrib>Smith, P. J.</creatorcontrib><creatorcontrib>Moots, R. J.</creatorcontrib><creatorcontrib>Hawkins, P. N.</creatorcontrib><title>Cytostatic therapy for AA amyloidosis complicating psoriatic spondyloarthropathy</title><title>British journal of rheumatology</title><addtitle>Rheumatology</addtitle><description>Psoriatic spondyloarthropathy (PSA) can occasionally be complicated by AA amyloid, and renal amyloidosis should be suspected in patients with PSA who have unexplained proteinuria. The diagnosis of amyloidosis can be made either histologically or by radiolabelled serum amyloid P component (SAP) scintigraphy. Prognosis is determined by the extent of organ involvement and associated impairment of function, and by the degree of response of the underlying disease to anti‐inflammatory therapy. A review of the literature identified less than a dozen cases of AA amyloidosis complicating PSA, and the outcome in most cases was poor. We report here the favourable clinical course of a middle‐aged Caucasian male patient with severe PSA who developed renal AA amyloidosis, in whom treatment with oral chlorambucil led to stabilization of the amyloid deposits and resolution of the associated nephrotic syndrome. We review the diagnosis and treatment of AA amyloidosis, including the management of patients with underlying inflammatory spondyloarthropathies, and propose the possible role of a therapeutic trial of anti‐tumour necrosis factor α in patients with amyloid complicating inflammatory rheumatic diseases.</description><subject>AA amyloidosis</subject><subject>Amyloidosis - drug therapy</subject><subject>Amyloidosis - etiology</subject><subject>Anti‐TNF</subject><subject>Arthritis, Psoriatic - complications</subject><subject>Biological and medical sciences</subject><subject>Chlorambucil</subject><subject>Chlorambucil - therapeutic use</subject><subject>Dermatology</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Kidney Diseases - drug therapy</subject><subject>Kidney Diseases - etiology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Psoriasis. Parapsoriasis. Lichen</subject><subject>Psoriatic spondyloarthropathy</subject><subject>Serum Amyloid A Protein - analysis</subject><subject>Spondylarthropathies - complications</subject><issn>1462-0324</issn><issn>1460-2172</issn><issn>1462-0332</issn><issn>1460-2172</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpd0F1rFDEUBuAgiv3QXyDIINi7scnka3K5LNoKC1ZREW_C2SSzm3ZmMk0y4Px7o7u04lUO5HkPhxehVwS_I1jRy7h38wA59GG3XN65HcHkCTolTDQ1prR5-jA37ASdpXSLMeaEts_RCWm44oLKU3SzXnJIGbI3Vd67CNNSdSFWq1UFw9IHb0PyqTJhmHpvCht31ZRC9H8TaQqjLQpi3scwQd4vL9CzDvrkXh7fc_Ttw_uv6-t68-nq43q1qQ1jJNfUtooB7gRxihjZUmiwNbhlgnFOrFLKGWu21ggBhmFFGsYElhwIkK3hlp6ji8PeKYb72aWsB5-M63sYXZiTlhQ3nChW4Jv_4G2Y41hu06SUwKVoaUH0gEwMKUXX6Sn6AeKiCdZ_2tb_tq0PbZfU6-PqeTs4-5g51lvA2yOAZKDvIozGp0fHOJVS8uLqg_Mpu18P_xDvtJBUcn3946f-rr7ctFebz3pNfwMLS50j</recordid><startdate>20030201</startdate><enddate>20030201</enddate><creator>Mpofu, S.</creator><creator>Teh, L. S.</creator><creator>Smith, P. J.</creator><creator>Moots, R. J.</creator><creator>Hawkins, P. N.</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20030201</creationdate><title>Cytostatic therapy for AA amyloidosis complicating psoriatic spondyloarthropathy</title><author>Mpofu, S. ; Teh, L. S. ; Smith, P. J. ; Moots, R. J. ; Hawkins, P. N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-3d894a0f61e91c783a20dc08464551d999ecdcbdc66ac40912446075a1a1bc5d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>AA amyloidosis</topic><topic>Amyloidosis - drug therapy</topic><topic>Amyloidosis - etiology</topic><topic>Anti‐TNF</topic><topic>Arthritis, Psoriatic - complications</topic><topic>Biological and medical sciences</topic><topic>Chlorambucil</topic><topic>Chlorambucil - therapeutic use</topic><topic>Dermatology</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Kidney Diseases - drug therapy</topic><topic>Kidney Diseases - etiology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Psoriasis. Parapsoriasis. Lichen</topic><topic>Psoriatic spondyloarthropathy</topic><topic>Serum Amyloid A Protein - analysis</topic><topic>Spondylarthropathies - complications</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mpofu, S.</creatorcontrib><creatorcontrib>Teh, L. S.</creatorcontrib><creatorcontrib>Smith, P. J.</creatorcontrib><creatorcontrib>Moots, R. J.</creatorcontrib><creatorcontrib>Hawkins, P. N.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mpofu, S.</au><au>Teh, L. S.</au><au>Smith, P. J.</au><au>Moots, R. J.</au><au>Hawkins, P. N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cytostatic therapy for AA amyloidosis complicating psoriatic spondyloarthropathy</atitle><jtitle>British journal of rheumatology</jtitle><addtitle>Rheumatology</addtitle><date>2003-02-01</date><risdate>2003</risdate><volume>42</volume><issue>2</issue><spage>362</spage><epage>366</epage><pages>362-366</pages><issn>1462-0324</issn><issn>1460-2172</issn><eissn>1462-0332</eissn><eissn>1460-2172</eissn><coden>BJRHDF</coden><abstract>Psoriatic spondyloarthropathy (PSA) can occasionally be complicated by AA amyloid, and renal amyloidosis should be suspected in patients with PSA who have unexplained proteinuria. The diagnosis of amyloidosis can be made either histologically or by radiolabelled serum amyloid P component (SAP) scintigraphy. Prognosis is determined by the extent of organ involvement and associated impairment of function, and by the degree of response of the underlying disease to anti‐inflammatory therapy. A review of the literature identified less than a dozen cases of AA amyloidosis complicating PSA, and the outcome in most cases was poor. We report here the favourable clinical course of a middle‐aged Caucasian male patient with severe PSA who developed renal AA amyloidosis, in whom treatment with oral chlorambucil led to stabilization of the amyloid deposits and resolution of the associated nephrotic syndrome. We review the diagnosis and treatment of AA amyloidosis, including the management of patients with underlying inflammatory spondyloarthropathies, and propose the possible role of a therapeutic trial of anti‐tumour necrosis factor α in patients with amyloid complicating inflammatory rheumatic diseases.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>12595637</pmid><doi>10.1093/rheumatology/keg101</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1462-0324
ispartof British journal of rheumatology, 2003-02, Vol.42 (2), p.362-366
issn 1462-0324
1460-2172
1462-0332
1460-2172
language eng
recordid cdi_proquest_miscellaneous_73025194
source MEDLINE; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection
subjects AA amyloidosis
Amyloidosis - drug therapy
Amyloidosis - etiology
Anti‐TNF
Arthritis, Psoriatic - complications
Biological and medical sciences
Chlorambucil
Chlorambucil - therapeutic use
Dermatology
Follow-Up Studies
Humans
Kidney Diseases - drug therapy
Kidney Diseases - etiology
Male
Medical sciences
Middle Aged
Psoriasis. Parapsoriasis. Lichen
Psoriatic spondyloarthropathy
Serum Amyloid A Protein - analysis
Spondylarthropathies - complications
title Cytostatic therapy for AA amyloidosis complicating psoriatic spondyloarthropathy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T09%3A12%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cytostatic%20therapy%20for%20AA%20amyloidosis%20complicating%20psoriatic%20spondyloarthropathy&rft.jtitle=British%20journal%20of%20rheumatology&rft.au=Mpofu,%20S.&rft.date=2003-02-01&rft.volume=42&rft.issue=2&rft.spage=362&rft.epage=366&rft.pages=362-366&rft.issn=1462-0324&rft.eissn=1462-0332&rft.coden=BJRHDF&rft_id=info:doi/10.1093/rheumatology/keg101&rft_dat=%3Cproquest_cross%3E73025194%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=195657683&rft_id=info:pmid/12595637&rfr_iscdi=true